COMMUNICATION
News & Press Release
Scilex Bio, a Controlling Interest of Joint Venture by Scilex Holding Company, Reports Phase 2 Trial
- DATE : 2024-12-16
- VIEWS : 2155
FILES
- Add(06714) 2 FL, Bangbae BLDG, 9, Myeongdal-ro, Seocho-gu, Seoul, Republic of Korea
- Tel+82-70-4018-8009
- Fax+82-02-3486-2613
- E-mailneuro_reply@neurobiogen.com
FAMILY SITE
COPYRIGHT ⓒ 2025 NEUROBIOGEN. All rights reserved